C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The Company has two proprietary and synergistic software platforms "Taxonomy3®" and "Conformetrix" that provide a significant competitive advantage when combined with an experienced management team. "Taxonomy3®" is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. "Conformetrix" determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. C4XD’s drug discovery engine was further strengthened by the acquisition of technologies from Molplex Ltd, in 2016, which included a software-based system which combines chemoinformatics, computational chemistry and artificial intelligence to optimise the drug discovery process. We have a hybrid business model of wholly-owned programmes and partnerships with pharma, biotech and academics.
The Company was founded as a spin-out from the University of Manchester and has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically.